SILEXION THERAPEUTICS CORP Additional Paid in Capital
SILEXION THERAPEUTICS CORP (SLXN) had Additional Paid in Capital of $61.33 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapital · last filed 2026-08-14
- 2026-06-30: Additional Paid in Capital $61.33M.
- 2026-03-31: Additional Paid in Capital $58.14M.
- 2025-12-31: Additional Paid in Capital $57.73M.
- 2025-09-30: Additional Paid in Capital $57.69M.
| Period end | Additional Paid in Capital | Additional Paid in Capital as first filed |
|---|---|---|
| 2026-06-30 | $61.33M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $58.14M S-1/A · filed 2026-08-10 | |
| 2025-12-31 | $57.73M 10-Q · filed 2026-08-14 | |
| 2025-09-30 | $57.69M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $47.60M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $47.57M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $39.26M S-1/A · filed 2026-08-10 | |
| 2024-09-30 | $37.00M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $11.40M 10-Q · filed 2024-08-29 | |
| 2023-12-31 | $11.34M 8-K · filed 2025-08-20 | $11.33M 10-Q · filed 2024-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |